Effective treatment of sensory neuropathies in peripheral neuropathies and spinal cord injury (SCI) is one of the most difficult problems in modern clinical practice. Cell therapy to release antinociceptive agents near the injured spinal cord is a logical next step in the development of treatment modalities. But few clinical trials, especially for chronic pain, have tested the potential of tran...

Retinoic acid (RA) induced the terminal differentiation of a human embryonal carcinoma cell line (NT2/D1) into several morphologically distinct cell types, including the postmitotic CNS neurons. Although RA has been suggested to play an important role in brain development, little is known about the molecular mechanism by which RA induces neuronal differentiation. In the present study, RNA finge...

In this paper, we study the category of quantale-valued preordered spaces. We show that it is a normalized topological and give characterization zero-dimensionality D-connectedness in Moreover, characterize explicitly each T0, T1, pre-T2, T2 NT2 Finally, examine how these are related to other full subcategory Ti(pre-T2(L-Prord)) (i=0,1,2) pre-T2(L-Prord), Ti (L-Prord) (i=1,2) L-Prord isomorphic.

Abstract Introduction Mazindol ER (extended-release), the first partial orexin-2 receptor agonist and triple mono-aminergic reuptake inhibitor, has demonstrated efficacy safety in significantly reducing excessive daytime sleepiness (EDS) cataplexy attacks narcolepsy type 1 (NT1) 2 (NT2) patients (POLARIS, Study NLS-1021). This was further studied an open-labeled extension (OLE) study (ClinicalT...

Abstract Introduction Efficacy secondary outcome measure Functional Outcomes of Sleep Questionnaire, Short Version (FOSQ-10] was collected in the Phase 2 (POLARIS, NLS-1021), multicenter (n=21) study mazindol ER adult participants with narcolepsy type 1 (NT1) or (NT2) (ClinicalTrials.gov Identifier: NCT04923594). Methods Adults diagnosed NT1 NT2 who were washed out medications at baseline inclu...